ATE401328T1 - Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren - Google Patents
Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitorenInfo
- Publication number
- ATE401328T1 ATE401328T1 AT04751862T AT04751862T ATE401328T1 AT E401328 T1 ATE401328 T1 AT E401328T1 AT 04751862 T AT04751862 T AT 04751862T AT 04751862 T AT04751862 T AT 04751862T AT E401328 T1 ATE401328 T1 AT E401328T1
- Authority
- AT
- Austria
- Prior art keywords
- secretasis
- arylsulfonylpiperidines
- bridged
- gamma
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47014603P | 2003-05-13 | 2003-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401328T1 true ATE401328T1 (de) | 2008-08-15 |
Family
ID=33452372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04751862T ATE401328T1 (de) | 2003-05-13 | 2004-05-11 | Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren |
Country Status (14)
Country | Link |
---|---|
US (1) | US7368457B2 (de) |
EP (1) | EP1641801B9 (de) |
JP (1) | JP2007501859A (de) |
CN (1) | CN1820010A (de) |
AR (1) | AR044294A1 (de) |
AT (1) | ATE401328T1 (de) |
CA (1) | CA2525124A1 (de) |
CL (1) | CL2004001011A1 (de) |
DE (1) | DE602004015110D1 (de) |
ES (1) | ES2308206T3 (de) |
MX (1) | MXPA05012268A (de) |
PE (1) | PE20050555A1 (de) |
TW (1) | TW200510405A (de) |
WO (1) | WO2004101562A2 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60144284D1 (de) * | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
DE602005020156D1 (de) * | 2004-06-30 | 2010-05-06 | Schering Corp | Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer |
CA2618087A1 (en) * | 2005-08-19 | 2007-03-01 | Elan Pharmaceuticals, Inc. | Bridged n-bicyclic sulfonamido inhibitors of gamma secretase |
EP2089383B1 (de) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten |
JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
AR076936A1 (es) | 2009-06-02 | 2011-07-20 | Vitae Pharmaceuticals Inc | Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1 |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
EP2542549B1 (de) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
EP2794565B1 (de) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis-b-viruzide |
CN104902885A (zh) | 2012-08-28 | 2015-09-09 | 爱尔兰詹森科学公司 | 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途 |
EA027194B1 (ru) | 2013-02-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
PT2997019T (pt) | 2013-05-17 | 2018-11-21 | Janssen Sciences Ireland Uc | Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
CN105431413B (zh) | 2013-07-25 | 2018-01-02 | 爱尔兰詹森科学公司 | 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
NZ717629A (en) | 2013-10-23 | 2021-12-24 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
JP6262885B2 (ja) * | 2014-03-06 | 2018-01-17 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. | オレキシン受容体拮抗剤としてのピペリジン誘導体 |
CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
BR112021015618A2 (pt) | 2019-02-22 | 2021-10-05 | Janssen Sciences Ireland Unlimited Company | Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04247081A (ja) * | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5員複素環酸アミド類 |
KR20020006626A (ko) * | 1999-02-26 | 2002-01-23 | 폴락 돈나 엘. | 신규한 술폰아미드 화합물 및 그의 용도 |
WO2002076440A2 (en) * | 2001-03-23 | 2002-10-03 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
-
2004
- 2004-05-11 ES ES04751862T patent/ES2308206T3/es not_active Expired - Lifetime
- 2004-05-11 WO PCT/US2004/014671 patent/WO2004101562A2/en active Application Filing
- 2004-05-11 PE PE2004000484A patent/PE20050555A1/es not_active Application Discontinuation
- 2004-05-11 CN CNA200480019637XA patent/CN1820010A/zh active Pending
- 2004-05-11 JP JP2006532943A patent/JP2007501859A/ja active Pending
- 2004-05-11 CA CA002525124A patent/CA2525124A1/en not_active Abandoned
- 2004-05-11 AR ARP040101597A patent/AR044294A1/es not_active Application Discontinuation
- 2004-05-11 US US10/842,783 patent/US7368457B2/en not_active Expired - Fee Related
- 2004-05-11 DE DE602004015110T patent/DE602004015110D1/de not_active Expired - Lifetime
- 2004-05-11 CL CL200401011A patent/CL2004001011A1/es unknown
- 2004-05-11 MX MXPA05012268A patent/MXPA05012268A/es not_active Application Discontinuation
- 2004-05-11 AT AT04751862T patent/ATE401328T1/de not_active IP Right Cessation
- 2004-05-11 EP EP04751862A patent/EP1641801B9/de not_active Expired - Lifetime
- 2004-05-11 TW TW093113229A patent/TW200510405A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007501859A (ja) | 2007-02-01 |
ES2308206T3 (es) | 2008-12-01 |
EP1641801B1 (de) | 2008-07-16 |
CN1820010A (zh) | 2006-08-16 |
EP1641801A2 (de) | 2006-04-05 |
AR044294A1 (es) | 2005-09-07 |
WO2004101562A2 (en) | 2004-11-25 |
DE602004015110D1 (de) | 2008-08-28 |
CA2525124A1 (en) | 2004-11-25 |
MXPA05012268A (es) | 2006-02-10 |
WO2004101562A3 (en) | 2005-02-10 |
EP1641801B9 (de) | 2009-02-25 |
TW200510405A (en) | 2005-03-16 |
US7368457B2 (en) | 2008-05-06 |
CL2004001011A1 (es) | 2005-03-18 |
US20040229902A1 (en) | 2004-11-18 |
PE20050555A1 (es) | 2005-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE401328T1 (de) | Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren | |
ATE402934T1 (de) | Malonamidderivate als gamma-secretaseinhibitoren | |
ATE437876T1 (de) | Hexahydropyridoisochinoline als dpp-iv- inhibitoren | |
ATE478868T1 (de) | Pyrrolodihydroisochinoline als pde10- inhibitoren | |
DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
ATE426599T1 (de) | Thiazolylpiperidin derivate als mtp inhibitoren | |
ATE525377T1 (de) | Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase | |
DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
IS8320A (is) | N-staðgengnir pýrasólýl-amidýl-bensimidasólýl | |
DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
DK1605897T3 (da) | Polyethelen-glycol-link-glp-1-forbindelser | |
DE60329282D1 (de) | Cyano-pyrrolidine als DPP-IV Inhibitoren | |
DE602004008303D1 (de) | Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3 | |
DE602004012154D1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren | |
ATE443706T1 (de) | Pyrrolotriazinverbindungen als kinaseinhibitoren | |
ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
DE60324208D1 (de) | Biarylsulfonamide als mmp-inhibitoren | |
DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
DE502004006055D1 (de) | 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren | |
ATE461926T1 (de) | Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer | |
ATE538787T1 (de) | Benzimidazol-derivative als raf-kinase-hemmer | |
ATE402700T1 (de) | Glycinamid-derivate als raf-kinase-hemmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |